Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium

Date Published: Sep 10, 2024

Provides Access to Growth Funding and Enhanced Access to Federal Projects

DURHAM, N.C., March 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been accepted into the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a part of the National Biopharmaceutical Manufacturing Partnership. The BioMap-Consortium has a $20 billion funding ceiling, through which it provides growth funding, as well as streamlined access to servicing government-funded manufacturing programs.

The BioMaP-Consortium supports the Biomedical Advanced Research and Development Authority (BARDA) and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services. This consortium seeks to expand the industrial and manufacturing base for medical countermeasures to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to meet the nation’s public health preparedness and response requirements.

Jeff Wolf, CEO of Scorpius, stated, "We are honored to be accepted as a member of the BioMaP-Consortium, which provides Scorpius opportunities to support biomanufacturing programs focused on the nation’s medical countermeasure programs, while providing biomanufacturing capacity and capabilities to defend against pandemics and other emerging threats. We look forward to building upon our track record of supporting infectious disease and biodefense programs on behalf of BARDA, the U.S. Department of Health & Human Services, and the U.S. Department of Defense.”

Scorpius Holdings, Inc.

Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as the collaboration expediting the development of critical solutions for public health threats, including pandemic preparedness and emerging infectious diseases; Scorpius collaborating with BARDA and other federal partners to support MCM product and technology development in critical areas such as vaccines and therapeutics; Scorpius’ extensive capabilities in biomanufacturing and its state-of-the-art production facilities uniquely positioning it to meet the evolving needs of government agencies tasked with responding to biological threats; the opportunity allowing the Company to leverage our manufacturing capabilities to support BARDA, the US government, and groups that service the US government in rapidly addressing public health emergencies; Scorpius playing an important role in ensuring preparedness for future public health emergencies such as pandemics and other biological risks by becoming part of the RRPV Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to, due to the collaboration, expedite the development of critical solutions for public health threats, including pandemic preparedness and emerging infectious diseases; the Company’s ability to expand its large molecule biomanufacturing CDMO services, attract new customers, profit from its pipeline and continue to grow revenue; the ability to capture a meaningful market share; the ability to generate meaningful cash flow and become cash flow positive; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com

BACK TO INDEX